论文部分内容阅读
为了解乳腺肿瘤患者血清CA15－3含量与细胞增殖抗原Ki-67，原癌基因C－erbB－2蛋白和抑癌基因P53蛋白的关系，应用单克隆抗体和免疫酶技术检测55例乳腺癌和82例良性乳腺肿瘤患者血清CA15－3含量，并应用免疫细胞化学技术检测Ki-67，C－erbB－2蛋白和P53蛋白。50名健康对照组CA15－3参考范围为3．7～20U／ml。乳腺癌和良性乳腺肿瘤各种指标的阳性率分别为，CA15－3：382％，8．5％；Ki-67：89．1％，48．8％；P53：60．0％，4．9％；C－erbB－2：49．1％，7．3％。CA15－3与P53和C－erbB－2之间存在着相关关系（P＜0．05），而CA15－3与Ki-67之间不存在相关关系（P＞0．05）。实验结果提示CA15－3具有较高的特异性，但灵敏度差，不可作为乳腺癌的筛查指标。P53和C－erbB－2在鉴别良恶性乳腺肿瘤中具有一定的价值。CA15－3可作为诊断乳腺癌早期复发的指标，可能与P53，C－erbB－2增强表达存在着内在的关系。
To investigate the relationship between serum CA15-3 levels in breast cancer patients and the relationship between cell proliferation antigen Ki-67, proto-oncogene C-erbB-2 protein and tumor suppressor gene P53 protein, monoclonal antibodies and immunoenzymatic techniques were used to detect 55 cases of breast cancer. Serum CA15-3 levels were detected in 82 patients with benign breast tumors. Ki-67, C-erbB-2 protein and P53 protein were detected by immunocytochemistry. The reference range of 50 healthy control group CA15-3 was 3.7-20 U/ml. The positive rates of various indicators of breast cancer and benign breast tumor were CA15-3:382%, 8.5%; Ki-67: 89.1%, 48.8%; P53: 60.0%, 4. 9%; C-erbB-2: 49.1 %, 7.3%. There was a correlation between CA15-3 and P53 and C-erbB-2 (P<0.05), but there was no correlation between CA15-3 and Ki-67 (P>0.05). The experimental results suggest that CA15-3 has high specificity, but the sensitivity is poor, and it cannot be used as a screening index for breast cancer. P53 and C-erbB-2 have certain value in the differentiation of benign and malignant breast tumors. CA15-3 can be used as an indicator to diagnose the early recurrence of breast cancer, and may be intrinsically related to the enhanced expression of P53 and C-erbB-2.